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data are available about the frequency and clinical features of sepsis in the
HAART era. The dramatical 25-fold decrease in frequency of HIV-related
bacteremia observed during the HAART era compared with preceding
years is associated with a less advanced HIV disease and immunodeficiency
and a reduced duration of related hospitalization, while an increased rate of
nosocomially-acquired pathogens was seen. The changing epidemiological,
microbiological, and clinical features ofHIV-related sepsis may significantly
influence the future management srrategies of HIV infection.
hiperferritinemic trend associated to increased hemosiderin were only on
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IMoP3SIIntracelluiar cytokines as early predictors of response
to highly active antiretroviral therapy (HAART)
E. Lew!, L. Gallagher2, M. Kuehnert!, D. Rimland2, S. Phillips!, M.
Hubbard', W. jarvis! , J. jason1
'Centersfor Disease Control and Prevention; 2Veterans Affairs Medical Center,
Atlanta, Georgia, United States
ObjectIve: To assess initial and early immune responses to HAART.
Methods: Peripheral blood mononuclear cells (PBMCs) from 12 HIV-l
infected patients were incubated with brefeldin-A and with or without
phorbol12-myristate l3-aeetate (PMA) and ionomycin. PBMCs were then
assessed for numerous surface antigens, memory/activation markers, and
intracellular cytokines, using four color cytoftuorometric analyses. Patients
were evaluated at pre-treatment and at 1, 2. and 3 weeks post-initiation of
HAART. Univariate analyses were done using Kruskal-Wallis tests.
Results: Six patienrs remained on therapy and returned for full follow-up.
All had a ~2-log decline in viral titers and/or decline to undetectable levels.
There were no significant changes in the median percentages and numbers of
CD4 + or CD8 + T-cells pre-therapy to week 3 (for CD4 + T-cells: 8.3%
to 8.8%, 138 to 138; for CD8+ T-cells: 27.2% to 24.0%, 436 to 371).
However, there were significant declines in the percentages ofCD4+ and
CD8+ lymphocytes spontaneously producing TNF-a (for CD4+ lym-
phocytes: 2.4% to 0.5%, p = 0.025; for CD8 + lymphocytes: 0.6% to
0.2%, p = 0.037). The percentage ofCD3+ T-cells spontaneously produ-
cing IL-4 also declined (1.8% to 0.8%, P = 0.004).
Conclusion: Spontaneous production ofTNF-a, a pro-inflammatory type I
cytokine, and of IL-4, a type II cytokine, decreased significantly within 3
weeks of successful HAART. None of the other immune parameters
assessed, including the percentages and numbers of CD4 + and CD8 + T-
cells and the percentage ofCD45RO + cells changed significantly. Changes
in the percentages of CD4 + and CD8 + lymphocytes spontaneously
producing TNF-a and of CD3 + T-cells spontaneously producing IL-4
may be early indicators of successful HAART.
IMOP36! serum ferritin levels as prognostic factor in AIDS
patients
Y. Franco!, M. Molina', A.J. Rodriguez3, M. Bermudez2
IMedidne Ill, Vargas Hospital ofCaracas; 2Pharmacology Laboratory; JVargas
Medical School, Caracas, Venezuela
objectives: Study the inverse relation between ferritin and CD4 lumpho-
cytes count to use it as prognostic marker in AIDS patients.
Methods: We included 40 patients with AIDS/HIV infection diagnosis. We
Studied serum ferritin levels and CD4 cells count, hematology and blood
chemistry. Ferritin levels were linked with Cf)4 eclb count, and with other
variables. Statistical analysis was at 95% confidence.
Results: Average measuremenrs were: CD4115.75/mm3, ferritin 322.62 ng/
mI, albumin 2.89 g/dl, ESR 71.07 seg. Inverse relation Ferritin/CD4 was at p
> 0.05 and Ferritin/Albumin was at p = 0.036 (OR 0.249). 22 patients
(55%) were hiperferritinemic (18 patients of these were AIDS C3). An
Condusions: Most patients presented hiperferritinemia, non explainable
due to different factors. Its direct relation to ESR and inverse to albumin
suggests its behavior as acute-phase reactant. therefore, serum ferritin levels
may be useful as direct and unspecific marker of opportunistic infections in
AIDS patienrs.
IMoP371 Evaluation of the Vldas HIV duo test In two
independent routine laboratories
W. Fierz1, M. jutzi2, P. Vernazzal, P. Erb2
IInstitute for Clinical Microbiology and Immunology, St. Gallen; 2Institute for
Medical Microbiology, University ofBasel Basel, Switzerland
Objective: To compare the Vidas HIV Duo with HIV 3. generation- and
p24-assays in two independent routine laboratories.
Methods: In St. GalIen, 4400 clinical samples were tested in parallel with the
Vidas HIV Duo (bioMerieux SA) and Cobas Core Anti-HIV-lfHIV-2 EIA
DAGS (F. Hoffmann-La Roche). In addition, 970 samples were tested for
p24 antigen with the HIVAG-l Monoclonal (Abbott). In Basel, 3007 sera
were compared with Vidas HIV Duo and AxSym HIV-l/HIV2 (Abbott). In
both laborarories, discrepant results were resolved with p24-antigen assays.
Western Blors, and evaluation of consecutive sera.
Results: In St. Gallen, from 4400 samples 31 (0.7%) were true positiv (TP)
and 16 (0.37%) falsch positiv (FP) in the Vidas HIV Duo, yielding a specifity
of 99.63%. In comparison, the specificity of the p24-antigen assay was
98.65% (13 FP (1.34%) samples). Seven primary HIVinfection were
detected as identified by a positive Vidas HIV Duo, a positive p24 antigen
assay and by clinical criteria. Four samples were negative in the AxSym and 5
in the Cobas Core. In Basel, from 3007 samples 36 (1.2%) were TP and 11
(0.37%) were FP in the Vidas Duo, yielding a specificity of 99.57%. In
comparison, the specificity ofthe AxSym was 99.9% (3 FP (0.1 %) samples).
Seven primary HIV-infection were identified, 4 samples were negative in
the AxSym.
Conclusions: The Vidas HIV Duo yielded in two independent laboratories
almost identical results. Although having a somewhat lower specificity
compared to the 3. generation assays tested, its strength and superiority lies in
the identification of primary HIV-infections. Moreover, for secreening of
primary HIV-infections the Vidas HIV Duo is superior to the Abbott p24-
assay.
IMoP3S! Multicenter evaluation of HIV DUO (bioM8rieux): An
assay for simultaneous detection of HIV antibodies and p24
antigen
P. Portincasal , R. Grill02, P. Pauri3 , M. G. Colao·, P. P. Valcavi', D.
Speziale2, G. Mazzarelli·, E. De Majo·, P. E. Varald03, G. Fadda2, C.
Chezzi', G. Deltori'
'Istituti di Microbiologia Universira di Parma; 2Universittl Cattolica del Sacro
Cuore di Roma; JUniversita di Ancona; ·Servizio ImmunosieroloJlia
Microbiologica Azienda Ospedaliera Careggi di rirenze, Italy
Objectives: To evaluate the performances ofa new HIV fourth generation
screening assay in a multicenter survey.
Methods: Second or third generation assaies and western blotting were used
to test sera belonging to hospitalized patients, blood donnors as well as
12 Abstracts
seroconversion pands in comparison with HIV DUO fourth generation
assay.
Results: HIV DUO showed sensitivity of 100% and specificity of 99.6%
among 1100 sera obtained from hospitalized patients or blood donnors. Tests
on sera obtained from commercial available as well as "in house" serocon-
version panels showed that HIV DUO is able to reveal an infected state, in II
out of 14 cases, earlier than conventional assay.
Conclusions: The new HIV DUO bioMerieux assay improves olds tests
performances in terms of sensitivity maintaining specificity at very high
levels.
IMoP39IAutomated TMA amplification and VIDAS detection
of a quantitative HIV-1 RNA test
]. 1. Bur~I,J.M. McCartyl, B. Weinbaum2, P.]. Levasseurl , P. M.
MacLean
IbioMerieux, Inc., Rockland, MA; 2Cen-Probe, Inc., San Diego, CA, United
States
Objectives: To develop a quantitative HIV-l viral load assay with AMP-
station for TMA (transcription-mediated amplification) and VIDAS for
detection.
Methods: Plasma samples containing HIV-I were added to a lysis reagent
containing IC (internal control) RNA. HIV-I genomic RNA and IC RNA
were captured onto paramagnetic particles with identical probes. Calibrators
and controls were processed similarly in parallel. After washing, particles
were resuspended and added directly to TMA reagent in a VIDAS PROBE
strip. Strips were placed in the AMPsration where a unit-dose enzyme pellet
was dissolved to initiate TMA. After amplification at 42°C for 60 minutes,
the TMA reaction was terminated by thermal inactivation of enzyme
activities. Strips were transferred to the VIDAS instrument and TMA
products (amplicons) detected in a three-part assay format designed for
high and low viral loads, and detection of the IC. Quantitation, based on
fluorescence kinetics, was achieved by interpolation to two overlapping
master calibration curves adjusted for each batch by run-specific calibrator
results.
Results: IC signals for undetectable HIV-1 samples reproducibly averaged
80 RFU/min, indicating that the IC RNA consistently verifies proper
sample processing, amplification and detection, including reproducible
performance of the AMPsration and VIDAS instruments. Linearity was
observed from 50 to > 100,000 HIV-I RNA copies/mi. Preliminary intra-
assay precision experiments showed CVs less than 30% for HIV-I RNA
inputs as low as 100 copies/mi. As part of an ongoing study, a blind
comparison was made to a peR method for the quantitation of clinical
specimens. Results, with a small number of specimens, showed 100%
concordance with a mean difference of 0.205 log10 RNA copies/mi.
Conclusions: The VIOAS PROBE Quantitative HIV-l Test gave accurate
vital load determination and should be useful in the management of HIV-I
infections.
IMoP40IEvaluation of a commercial test for the detection of
HIV-1 antibodies in urine samples
1. Matasl,]. Almeda2,]. Casabona2, V. Gonzalezl , R. Muga3, M. Vall',
B. Sanz', F. Bolaos, V. Ausina'
IServei de Microbiologia; 2CEESCAT; JMedicina Imerna; Hospital Germans
TritU i Pujol de Badalona; 'Unitat de Malalties de Transmissio Sexual, CAP
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IMo02S1 Human herpesvirus-6 infection after liver
transplantation
I. Lautenschlager, K. Linnavuori, M. Lappalainen,]. Suni, K. Hockerstedt
Departments of Virology and Surgery, Helsinki University Central Hospital,
Helsinki, Finland
Human herpesviruHI (HHV-6) infection has recently been reported in liver
transplant patients. In addition to clinical symptoms, such as fever, HHV-6
Drassanes Barcelona; sUnitat drogotlependincies Hospital Bellvitge, Hospitalet
tie Llobregal, Barcelona, Spain
Objective: Evaluation of the test Seradyn® Sentinel HIV-I Urine EIA
(Seradyn Inc, Indianapolis IN) to detect HIV-I antibodies in urine samples.
Methods: Urine and serum samples were obtained from 151 patients
attended in a sexually transmitted disease clinic (STDC) and from 97 patients
from two drug dependency treatment centres (DDTC). HIV-l antibody
detection in serum was performed using the routine EIA test (Bioelisa HIV-l
+ 2, Biokit). Positive results were confirmed by Western-blot test (New
Lab Blot I, Sanofi). HIV-l antibody detection in urine, samples was
performed according, to the manufacturer's recommendations. Reactive
urine samples were confirmed by the adaptation of me Biotest H1V-l
Western-blot test.
Results: 248 patients were included, 55 (22%) having H1V-l antibodies
(46% ofthe DDTC's patients and 6.6% ofthe STDC's patients). Discordant
results were found in five cases: 2 urine samples from HIV-l, positive
patients were negative, and 3 urine samples with EIA positive result ftom
HIV-I negative patients. None of them were confirmed by urine western-
blot test. Sensitivity, specificity and positive and negative predictive values
(pPV and NPV) for both groups are the following:
Positive Neg.tive Sensitivity Specificity PPV NPV
HIV HIV
STDC 10 141 0.83 0.99 0.90 0.90
DDTC 45 52 1.00 0.% 0.95 1.00
Tot21 55 193 0.% 0.98 0.94 0.98
COndusions: Seradyn® Sentinel HIV-l Urine EIA has proven to be a
reliable tool for large screening programmes. Additionally, ease ofspecimen
collection and safety issue make this test particularly attractive for screening
programmes.
IMoP41 IGenotypic resistance to NRTls measured by UPA
HIV·1 RT
F. Garcia, M. Alvarez, N. M. Martinez, P. Morara, M. C. Hemal, F.
GarciaJr.,]. Hernandez, I. Lopez, G. Piedrola, M. C. Maroro
Microbiology and 1. Diseases Units, Universitary Hospital, Granada, Spain
Objective: to evaluate the incidence of genotypic resistance to NRTis at
HIV-l infected patients from Southern Spain and with HAART.
Patients and Methods: 42 patients on HAART (16 females, 26 males; mean
age: 34.46 ± 8.41; risk factors: 20 IYDU, 17 heterosexual, 4 homosexual
males and 1 transfusion) and with virological failure have been studied.
Previous treatments and genotypic resisrance (INNO LIPA HIV-l RT)
were studied.
Results: 32 patients showed resistance to AZT (76.2%), 8 to 3TC (19%), 2
(4.7%) to DOl and 2 (4.7%) to DOC. Related to the number of patients/
year on treatment with each NRTI, the incidence of the resistance was: 25.8
(17.59-26.85) for AZT, 19.5 (8.4-38.3) for 3TC, 6.4 (0.7-23.2) for DOC
and 4.4 (0.5-16) for 001. No influence of sex or risk factor on AZT
genotype resistance was observed. After 6 months of resistance testing and
therapy modification viral load was reduced as follows: 3 Logs, 11.5%; 2
Logs, 11.5%; and 1 Log, 23%.
Conclusions: the highest incidence ofgenotype resistance to Nitres at HIV-l
infected patients from Southern Spain was for AZT, followed by 3TC. For
001 and DDC a lower incidence of genotype resistance has been observed.
may infect the transplant and cause graft dysfunction. In this study, the
frequency and clinical findings of HHV-6 infection were investigated in
liver transplant patients.
Methods: Consecutive 100 adult liver allograft recipients transplanted
during 1996-99 were included in the study. The patients were frequently
monitored for HHV-6 during 6 months after transplantation. The diagnosis
ofHHV-6 infection was based on the demonstration ofviral antigens in the
peripheral blood mononuclear cells, and in liver biopsies, by immunoper-
oxidase staining using monoclonal antibodies against HHV-6 antigens, and
on serology. The patients were also monitored for cytomegalovirus (CMV).
